已收盤 02-06 16:00:00 美东时间
-0.590
-3.01%
今日重点评级关注:Canaccord Genuity:维持Wave Life Sciences Ltd."买入"评级,目标价从40美元升至43美元;花旗:维持Palantir Technologies"买入"评级,目标价从235美元升至260美元
02-04 12:15
Leerink Partners initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $31.
02-03 20:29
JP Morgan analyst Jessica Fye initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Overweight rating and announces Price Target of $30.
02-03 20:27
Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing
01-13 19:35
Aktis Oncology涨24.44%,最新市值11.76亿美元;Lafayette Digital Acquisition Corp. I跌0.20%,最新市值0.00亿美元;Atlas Critical Minerals (Uplisting)跌41.33%,最新市值0.39亿美元;
01-10 06:00
Aktis Oncology今晚将在纳斯达克上市,通过发行1770万股股票,每股定价18美元。
01-09 16:43
专注于研发实体瘤靶向放射性药物的临床Ⅰ期生物科技企业Aktis Oncology(AKTS.US)于上周五向美国证券交易委员会(SEC)提交申请,拟通过首次公开...
2025-12-22 16:05
Akoustis Technologies ( ($AKTS) ) has issued an update. Akoustis Technologies, ...
2024-09-21 04:50
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
2024-08-19 07:00
Akoustis Technologies (AKTS) has shared an update. Akoustis Technologies, Inc. ...
2024-08-09 05:18